Vaccine prioritisation and commentary, monoclonal antibodies (-mabs), non-pharmaceutical interventions

Peer reviewed journals featured:

- Multiple papers on COVID-19 vaccines:
  - A review of COVID-19 vaccine strategies and challenges [here](#)
  - Model-informed COVID-19 vaccine prioritisation strategies by age and serostatus [here](#)
    and associated perspective [here](#)
  - A survey on Australians’ willingness to be vaccinated (conducted May 2020) [here](#)
  - Commentary on:
    - Social media companies’ failure to tackle vaccine misinformation [here](#)
    - Allergic reactions including anaphylaxis after Pfizer-BioNTech vaccine [here](#)
    - Vaccinating children against COVID-19, the lessons of measles [here](#)
    - Positioning government leaders in US vaccine prioritisation frameworks [here](#)
- Randomised controlled trials on
  - tocilizumab for severe or critical COVID-19 [here](#)
  - the effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in mild to moderate COVID-19 [here](#) and associated commentary [here](#)
- An experimental study on interventions to increase the use of a COVID-19 contact tracing app [here](#)
- A cohort study on non-steroidal anti-inflammatory drugs and COVID-19 related death [here](#)
- A US national survey on forgone medical care among adults in the initial phase of COVID-19 [here](#)
- Modelling studies on:
  - Altering length of quarantine, testing strategies and contact tracing [here](#)
  - The worldwide effects of non-pharmaceutical interventions on COVID-19 [here](#)
- Commentary on:
  - Unintended consequences of hand sanitiser use in COVID-19 pandemic [here](#)
  - What health care can learn from Operation Warp Speed [here](#)

Letters and correspondence discussed:

- SARS-CoV-2 reinfection and structured serological testing [here](#)
- Media and filming in COVID-19 filled hospitals [here](#)
- Response to a previously published article on the neonatal immune response to SARS-CoV-2 infection [here](#) and authors' reply [here](#)
Guidance and reports

- The UK National Institute for Health and Care Excellence (NICE) released an evidence summary on sarilumab [here](#).

News and blogs

- Revisiting the UK strategy for delaying the second dose of the Pfizer COVID-19 vaccine [here](#).
- Increasing uptake of COVID-19 contact tracing apps [here](#).
- COVID-19 vaccines might lose potency against new viral variants [here](#).
- Fast-spreading COVID-19 variant can elude immune responses [here](#).
- What new COVID-19 variants mean for schools is not yet clear [here](#).

The Critical Intelligence Unit is actively tracking developments on SARS-CoV-2 variants and on vaccines. An evidence check on variants is available [here](#).

[Click here](#) to subscribe to the daily evidence digest.